Monday, August 21, 2017

UNITY Biotechnology Adds $35M

San Francisco-based UNITY Biotechnology, which is developing biopharmaceuticals aimed at preventing, halting or reversing diseases of aging, has raised $35M in additional Series B funding, the company said last week. The new funding came from INVUS Opportunities, Three Lakes Partners, Cycad Group, COM Investments, and Pivotal Alpha Limited. The round also included ARCH Venture Partners, Baillie Gifford, Fidelity Management and Research Company, Partner Fund Management, and Venrock, plus Bezos Expeditions, Vulcan Capital, Founders Fund, WuXi PharmaTech, and Mayo Clinic Ventures. UNITY says it has now raised a total of $151M in funding in its Series B funding.